AlliedCel inks agreement with JUNTEN BIO for manufacturing RMP

Sysmex Corporation announces that AlliedCel Corporation, a joint venture with JCR Pharmaceuticals Co., Ltd has entered into a license agreement with JUNTEN BIO Co., Ltd. to play roles in the domestic manufacturing and sales of regenerative medicine products for immune tolerance induction with inducible inhibitory T-cells (JB-101).

AlliedCel was established in October 2022 for carrying out research and development, manufacture and sales of regenerative medicine products using stem cells such as hematopoietic stem cells and other cells. In addition to the project using hematopoietic stem cell proliferation technology that AlliedCel has been promoting since its establishment, it will also move ahead on studying the possibilities of other technological developments and commercialization.

AlliedCel has recently concluded a license agreement with JUNTEN BIO to take the roles in the domestic manufacturing and sales of regenerative medicine products for immune tolerance induction with inducible inhibitory T-cells (JB-101). Inducible inhibitory T-cells (JB-101) was developed by JUNTEN BIO based on the research conducted by Juntendo University.

Under the supervision of Juntendo University, inducible inhibitory T-cells (JB-101) are being used in an investigator-initiated study for living donor liver transplantation patients for the indication of suppressing immune rejection and supporting withdrawal (induction of immune tolerance) from immunosuppressants that transplant patients need to take orally continuously throughout their lives when administered to them after organ transplantation. Inducible inhibitory T-cells (JB-101) was designated under Japan’s Ministry of Health, Labour and Welfare’s Sakigake Designation System in 2020 as a candidate for an innovative regenerative medicine product originating from Japan and leading the world. It is scheduled for manufacturing and sales application in fiscal year 2025. Reducing the dosage of, or withdrawing, immunosuppressants is expected to not only reduce such risks as complications or infections after an organ transplant, but also to improve the survival rate of transplanted organs.

Sysmex and JCR have combined Sysmex’s expertise in quality control testing technology and its knowledge of workflows efficiency using robotics technology, including IoT with JCR’s track record and know-how in developing, manufacturing, and selling regenerative medicine and other products, to establish AlliedCel for R&D and early commercialization of regenerative medicine products using stem cells and other cells. The addition of inducible inhibitory T-cells (JB-101) to AlliedCel’s existing businesses will enable us to provide appropriate treatment options to patients sooner through regenerative medicine and other products.
MB Bureau